Abstract
Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in all laboratories of pathology. This method is generally used for diagnostic purposes, but several studies have investigated the sensitivity and specificity of different immunohistochemical antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical examination of the works comparing the consistency of IHC expression and conventional molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed. Summarizing, data on sensitivity and specificity of antibodies against ALK and ROS1 are very consistent and time has come to trust in IHC at least as a cost-effective screening tool to identify patients with rearranged tumors in clinical practice. On the other hand, mutant-specific antibodies against EGFR demonstrate a good specificity but a lowto- fair sensitivity, raising some cautions on their employment as robust predictive biomarkers. A brief comment on preliminary experiences with antibodies against BRAF, RET, HER2 and c-MET is also included.
Keywords: ALK, EGFR, gene mutation, immunohistochemistry, lung cancer, molecular biology, ROS1.
Current Drug Targets
Title:Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
Volume: 18 Issue: 1
Author(s): Giulio Rossi, Moira Ragazzi, Ione Tamagnini, Maria C. Mengoli, Giada Vincenzi, Fausto Barbieri, Silvia Piccioli, Alessandra Bisagni, Tiziana Vavala, Luisella Righi, Silvia Novello, Francesco Gelsomino and Marcello Tiseo
Affiliation:
Keywords: ALK, EGFR, gene mutation, immunohistochemistry, lung cancer, molecular biology, ROS1.
Abstract: Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in all laboratories of pathology. This method is generally used for diagnostic purposes, but several studies have investigated the sensitivity and specificity of different immunohistochemical antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical examination of the works comparing the consistency of IHC expression and conventional molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed. Summarizing, data on sensitivity and specificity of antibodies against ALK and ROS1 are very consistent and time has come to trust in IHC at least as a cost-effective screening tool to identify patients with rearranged tumors in clinical practice. On the other hand, mutant-specific antibodies against EGFR demonstrate a good specificity but a lowto- fair sensitivity, raising some cautions on their employment as robust predictive biomarkers. A brief comment on preliminary experiences with antibodies against BRAF, RET, HER2 and c-MET is also included.
Export Options
About this article
Cite this article as:
Rossi Giulio, Ragazzi Moira, Tamagnini Ione, Mengoli C. Maria, Vincenzi Giada, Barbieri Fausto, Piccioli Silvia, Bisagni Alessandra, Vavala Tiziana, Righi Luisella, Novello Silvia, Gelsomino Francesco and Tiseo Marcello, Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450116666150330114441
DOI https://dx.doi.org/10.2174/1389450116666150330114441 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Functionalized Magnetic Nanostructures for Anticancer Therapy
Current Drug Targets Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases
Current Genomics Lipid Based Aqueous Core Nanocapsules (ACNs) for Encapsulating Hydrophillic Vinorelbine Bitartrate: Preparation, Optimization, Characterization and In vitro Safety Assessment for Intravenous Administration
Current Drug Delivery Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics XIST: A Meaningful Long Noncoding RNA in NSCLC Process
Current Pharmaceutical Design Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry The Cooperative Effect between Polybasic Region (PBR) and Polysialyltransferase Domain (PSTD) within Tumor-Target Polysialyltranseferase ST8Sia II
Current Topics in Medicinal Chemistry Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging Changes of Expression of the Protein C Pathway Components in LPSInduced Endotoxemia–Implication for Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry The Changing Face of Tobacco Use Among United States Youth
Current Drug Abuse Reviews Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies Bromodomain-Containing Protein 4: A Druggable Target
Current Drug Targets From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions
Current Drug Targets